Compare AXGN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | IRON |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2013 | 2020 |
| Metric | AXGN | IRON |
|---|---|---|
| Price | $44.49 | $73.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $42.33 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 1.2M | 533.7K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $225,208,000.00 | N/A |
| Revenue This Year | $20.57 | N/A |
| Revenue Next Year | $16.68 | $283.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.21 | N/A |
| 52 Week Low | $10.50 | $40.00 |
| 52 Week High | $46.00 | $99.50 |
| Indicator | AXGN | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 63.17 |
| Support Level | $29.48 | $70.29 |
| Resistance Level | $44.83 | $82.70 |
| Average True Range (ATR) | 2.34 | 2.87 |
| MACD | 0.05 | 0.30 |
| Stochastic Oscillator | 71.81 | 90.74 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.